[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20021401L - Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser - Google Patents

Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser

Info

Publication number
NO20021401L
NO20021401L NO20021401A NO20021401A NO20021401L NO 20021401 L NO20021401 L NO 20021401L NO 20021401 A NO20021401 A NO 20021401A NO 20021401 A NO20021401 A NO 20021401A NO 20021401 L NO20021401 L NO 20021401L
Authority
NO
Norway
Prior art keywords
compounds
formula
pharmaceutical preparations
preparations containing
quinazoline
Prior art date
Application number
NO20021401A
Other languages
English (en)
Other versions
NO20021401D0 (no
Inventor
Andrew Austen Mortlock
Nicholas John Keen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922159.0A external-priority patent/GB9922159D0/en
Priority claimed from GBGB9922152.5A external-priority patent/GB9922152D0/en
Priority claimed from GBGB9922156.6A external-priority patent/GB9922156D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20021401D0 publication Critical patent/NO20021401D0/no
Publication of NO20021401L publication Critical patent/NO20021401L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Anvendelsen av en forbindelse av formel (I). eller et salt, ester eller amid derav, hvor X er 0, eller S, S(0) eller S(0), NH eller NRhvor Rer hydrogen eller C-alkyl; Ra er en 3-kinolingruppe eller en gruppe av underformel (i). hvor R, Rog Rer forskjellige spesifikke organiske grupper, i fremstillingen av et medikament for bruk i inhiberingen av aurora2-kinase.Nye forbindelser av formel (I) og farmasøytiske preprarater som er nyttige i behandlingen av kreft er også beskrevet og påberopt.
NO20021401A 1999-09-21 2002-03-20 Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser NO20021401L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9922159.0A GB9922159D0 (en) 1999-09-21 1999-09-21 Chemical compounds
GBGB9922152.5A GB9922152D0 (en) 1999-09-21 1999-09-21 Chemical compounds
GBGB9922156.6A GB9922156D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003556 WO2001021594A1 (en) 1999-09-21 2000-09-18 Quinazoline compounds and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO20021401D0 NO20021401D0 (no) 2002-03-20
NO20021401L true NO20021401L (no) 2002-05-21

Family

ID=27269803

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021401A NO20021401L (no) 1999-09-21 2002-03-20 Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser

Country Status (20)

Country Link
US (1) US7081461B1 (no)
EP (1) EP1218356A1 (no)
JP (1) JP2003509497A (no)
KR (1) KR20020032608A (no)
CN (1) CN1391561A (no)
AU (1) AU763242B2 (no)
BG (1) BG106491A (no)
BR (1) BR0014133A (no)
CA (1) CA2384282A1 (no)
CZ (1) CZ20021010A3 (no)
EE (1) EE200200149A (no)
HK (1) HK1046688A1 (no)
HU (1) HUP0204413A3 (no)
IL (1) IL148489A0 (no)
IS (1) IS6304A (no)
NO (1) NO20021401L (no)
PL (1) PL354923A1 (no)
SK (1) SK3832002A3 (no)
TR (1) TR200200749T2 (no)
WO (1) WO2001021594A1 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135466B2 (en) 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN100347169C (zh) 2000-08-21 2007-11-07 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
EP1326860A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives
EP1326859A1 (en) 2000-10-13 2003-07-16 AstraZeneca AB Quinazoline derivatives with anti-tumour activity
AU2002217999A1 (en) 2000-11-01 2002-05-15 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
EP1381599B1 (en) * 2001-04-19 2008-09-24 Astrazeneca AB Quinazoline derivatives
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
CN1753903B (zh) * 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
BR0306982A (pt) 2002-01-17 2004-10-26 Neurogen Corp Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, métodos para reduzir a condutância de cálcio de um receptor da capsaicina celular, para inibir a ligação de ligando vanilóide a um receptor da capsaicina in vitro e em um paciente, para tratar uma condição responsiva à modulação do receptor da capsaicina em um paciente, para tratar a dor em um paciente, para tratar coceira em um paciente, para tratar tosse ou soluço em um paciente, promover a perda de peso em um paciente obeso, e para determinar a presença ou ausência de receptor da capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60327323D1 (de) * 2002-07-09 2009-06-04 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
WO2004006846A2 (en) 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
CA2503371C (en) 2002-11-04 2011-01-11 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
AU2003294142A1 (en) * 2002-12-24 2004-07-22 Astrazeneca Ab Therapeutic quinazoline derivatives
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
EP1660090B1 (en) 2003-08-14 2012-11-21 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DE602004022318D1 (de) * 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CA2540342A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
PL1746999T3 (pl) 2004-05-06 2012-07-31 Warner Lambert Co 4-fenyloaminochinazolin-6-yloamidy
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2599328C (en) 2005-02-23 2012-04-17 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
JP2008535876A (ja) 2005-04-14 2008-09-04 エフ．ホフマン−ラ ロシュ アーゲー アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509224D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EP1971601B1 (en) 2005-11-15 2009-10-21 Array Biopharma Inc. N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
WO2009030224A2 (de) * 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
US20090291971A1 (en) * 2007-11-01 2009-11-26 Wyeth Heteroaryl ethers and processes for their preparation
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
WO2010068311A1 (en) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor
CA2733153C (en) * 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN101857588B (zh) * 2010-06-08 2013-11-27 东南大学 4-芳香胺基喹唑啉类衍生物及其用途
CN102850280B (zh) * 2011-06-30 2015-06-10 陕西师范大学 6,7-二烷氧基-4-取代苯基氨基喹唑啉类化合物及其制备方法
KR101645112B1 (ko) 2013-03-06 2016-08-02 아스트라제네카 아베 표피 성장 인자 수용체의 활성화 돌연변이체 형태의 퀴나졸린 억제제
US10548897B2 (en) 2015-04-16 2020-02-04 Icahn School Of Medicine At Mount Sinai KSR antagonists
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN113354591B (zh) * 2021-06-09 2023-03-24 广东湛江海洋医药研究院 烷氨基喹唑啉的合成及其抗肿瘤活性

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409930A (en) * 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (no) * 1994-11-12 1997-12-01 Zeneca Ltd
DE122005000053I2 (de) * 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
NZ330868A (en) * 1996-02-13 2000-01-28 Zeneca Ltd 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (es) * 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
WO1999061428A1 (en) * 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor

Also Published As

Publication number Publication date
JP2003509497A (ja) 2003-03-11
TR200200749T2 (tr) 2002-06-21
HUP0204413A2 (en) 2003-05-28
SK3832002A3 (en) 2002-11-06
EE200200149A (et) 2003-04-15
CA2384282A1 (en) 2001-03-29
BG106491A (bg) 2002-12-29
US7081461B1 (en) 2006-07-25
KR20020032608A (ko) 2002-05-03
CN1391561A (zh) 2003-01-15
PL354923A1 (en) 2004-03-22
CZ20021010A3 (cs) 2002-06-12
IS6304A (is) 2002-03-18
IL148489A0 (en) 2002-09-12
AU7432500A (en) 2001-04-24
EP1218356A1 (en) 2002-07-03
BR0014133A (pt) 2002-06-11
HK1046688A1 (zh) 2003-01-24
WO2001021594A1 (en) 2001-03-29
NO20021401D0 (no) 2002-03-20
HUP0204413A3 (en) 2003-07-28
AU763242B2 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
NO20021401L (no) Kinazolinforbindelser og farmasöytiske preparater som inneholder slike forbindelser
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
NO20013768D0 (no) Kjemiske forbindelser
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
ATE361916T1 (de) Pyrimidine verbindungen
SE0202463D0 (sv) Novel compounds
MY120064A (en) Indole derivatives as inhibitors or factor xa
NO900306L (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
DK0610487T3 (da) Nye aminosyrederivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
BR0007589A (pt) Inibidores da proliferação de células
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
NO996108L (no) 9-oksinerytromycinderivater
RU94022743A (ru) Амидо- или карбамидо-производные, обладающие антигиперхолестериновой активностью, и фармацевтическая композиция на их основе
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
BRPI0408338A (pt) piperidinas substituìdas como novos inibidores de mdm2-p53
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
NO324229B1 (no) 2-hydroksymutilinkarbamat-derivater, anvendelse derav, farmasoytisk sammensetning samt fremgangsmate for fremstilling av en slik forbindelse
DK0992509T3 (da) Nye makrolid-derivater
FI860878A (fi) Aminosyraderivat och foerfarande foer deras framstaellning.
SE9701304D0 (sv) Compounds
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
ATE247964T1 (de) Als inhibitoren der aicarftnützliche verbindungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application